In this interview SI alluded to the second interim analysis could show overwhelming efficacy, and DSMB might recommend trial stopping early!! However, SI seems to want to continue to completion. Although I think the decision to continue lies in MSb's hands, I wonder how this will play out with the FDA and Trump. What will happen to the share price? More volatile? Never a dull moment investing in Mesoblast
In this interview SI alluded to the second interim analysis...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
0.035(2.89%) |
Mkt cap ! $1.421B | |||
| Open | High | Low | Value | Volume |
| $1.21 | $1.25 | $1.18 | $4.096M | 3.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22000 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 36989 | 4 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |